• Citations Per Year
Learn More
3589 Background: We planned to conduct a phase II clinical study of combination therapy with irinotecan and S-1, a new oral anticancer drug of the fluorinated pyrimidine type. We reported the interium reports of this study in colorectal cancer patients at GI cancer Symposium 2006. METHODS The antitumor effect was the primary endpoint, while the safety,(More)
  • 1